{"entity":{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","aka":["Jacobio Pharmaceuticals Co., Ltd.","Jacobio Pharmaceuticals Group Co., Ltd."],"tldr":"Jacobio Pharmaceuticals is a Beijing cancer-drug developer listed in Hong Kong whose KRAS G12C inhibitor glecirasib was approved in China in 2025 for previously treated lung cancer, and whose pan-KRAS inhibitor JAB-23E73 is licensed to AstraZeneca.","summary":"Jacobio Pharmaceuticals, listed in Hong Kong, develops targeted cancer drugs aimed mainly at the KRAS pathway. In May 2025 China's drug regulator approved its KRAS G12C inhibitor glecirasib for non-small-cell lung cancer with a KRAS G12C mutation after at least one earlier systemic therapy, based on a pivotal single-arm phase 2 trial in China; the Greater China rights are licensed to Shanghai Allist Pharmaceuticals. In December 2025 it licensed its pan-KRAS inhibitor JAB-23E73 to AstraZeneca for the world outside mainland China, with joint development and co-commercialisation in mainland China, and it received the USD 100 million upfront payment in March 2026. On ClinicalTrials.gov it sponsors 6 interventional cancer trials (phase 1/2) of JAB-30355, JAB-2485, JAB-23E73 and JAB-8263 in solid tumours, including ER-positive and triple-negative breast cancer and tumours with ARID1A mutations.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.jacobiopharma.com"},{"label":"HKEX: glecirasib approved for market launch (22 May 2025)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0522/2025052200747.pdf"},{"label":"HKEX: licence and collaboration agreement with AstraZeneca for JAB-23E73 (21 December 2025)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1221/2025122100421.pdf"},{"label":"HKEX: USD 100 million upfront received from AstraZeneca (30 March 2026)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0330/2026033000113.pdf"},{"label":"ClinicalTrials.gov: trials sponsored by Jacobio Pharmaceuticals","url":"https://clinicaltrials.gov/search?spons=Jacobio%20Pharmaceuticals"}],"tags":["ctgov-sponsor","china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["glecirasib"],"companies":["astrazeneca","allist"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06386146","nct05490472","nct06973564","nct04686682","nct06959615","nct07640295"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Freshened 29 October 2026 from the company's HKEX announcements of 22 May 2025 (glecirasib approval), 21 December 2025 (AstraZeneca licence) and 30 March 2026 (upfront payment received). It was previously recorded from the registry alone; listing and approval facts are now sourced. No acquisition or renaming found."],"hq":"Beijing, China","country":"CN","companyType":"biotech","website":"https://www.jacobiopharma.com","ticker":"1167.HK","stage":"public","investors":[],"funding":[]},"route":"/companies/jacobio-pharmaceuticals/","neighbours":{"drug":[{"id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/"}],"trial":[{"id":"nct04686682","kind":"trial","name":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","route":"/trials/nct04686682/"},{"id":"nct06959615","kind":"trial","name":"A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration","route":"/trials/nct06959615/"},{"id":"nct06973564","kind":"trial","name":"JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","route":"/trials/nct06973564/"},{"id":"nct05490472","kind":"trial","name":"JAB-2485 Activity in Adult Patients With Advanced Solid Tumors","route":"/trials/nct05490472/"},{"id":"nct06386146","kind":"trial","name":"JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","route":"/trials/nct06386146/"},{"id":"nct07640295","kind":"trial","name":"Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations","route":"/trials/nct07640295/"}],"cancer":[{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/"}]}}